FDA may limit anemia drug use for kidney disease

Oct 14, 2010 By MATTHEW PERRONE , AP Health Writer

(AP) -- The Food and Drug Administration is considering new restrictions on widely used anemia drugs that appear to double the risk of stroke in patients with kidney disease.

The FDA posted its safety review of the three blood-boosting medications from Amgen Inc. on Thursday, focusing on their use in patients with chronic who are not yet sick enough to receive dialysis.

The medicines - Procrit, Aranesp and Epogen - are multibillion dollar sellers because of their ability to boost oxygen-carrying , reducing the need for painful blood transfusions. But sales have fallen sharply since 2007, when the FDA added the first of several safety warnings to the drugs, based on evidence they can cause tumor growth and hasten death in cancer patients. The drugs are no longer used in patients with several types of cancers.

Anemia, which causes weakness and shortness of breath, is a side effect of chemotherapy and .

Now the FDA is reviewing a study published last year that showed kidney disease patients taking Aranesp were twice as likely to experience stroke compared with those taking a dummy treatment. The goal of the study was to show that the drug could prevent heart attack, stroke and other heart-related problems, as had been assumed for years.

But FDA reviewers, using the chemical name for Aranesp, said in their posting that the "evidence raises considerable doubt about the safety and advisability of using darbepoetin in this manner."

Amgen has argued that its drugs should continue to be used because they help avoid blood transfusions, which carry their own risks. But the FDA's scientists point out that 15 percent of patients who took the company's drug still needed transfusions, compared with 25 percent of those taking a .

"Treatment did not eliminate the risk of requiring (red blood cell) transfusions," states the FDA review.

On Monday the agency will ask a panel of outside experts to review the data and make recommendations on how to safely use the drugs. Panelists could recommend bolstered warning labels, additional studies or lower doses of the drugs. The FDA is not required to follow the group's advice, although it often does.

Amgen, based in Thousand Oaks, Calif., makes all three drugs. Procrit is sold by Johnson & Johnson's Centocor Ortho Biotech division, under a long-standing agreement between the companies.

Last year the drugs - known as erythropoiesis stimulating agents - had combined sales of $6.3 billion, according to health data firm IMS Health.

Pre-dialysis kidney patients contributed 30 percent of Aranesp's revenue last year, estimates Robyn Karnauskas, an analyst at Deutsche Bank. New FDA restrictions would shave $86 million in sales off the drug, he estimates, which would have a minimal effect on Amgen's revenue. Amgen, one of the giants of the biotech drug industry, had total revenue exceeding $14.6 billion last year.

Explore further: FDA approves hard-to-abuse narcotic painkiller

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Study finds stroke risk from anemia drug Aranesp

Oct 31, 2009

(AP) -- A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick ...

Anemia drugs under scrutiny

Mar 13, 2008

U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.

FDA questions safety of Glaxo kidney cancer drug

Oct 01, 2009

(AP) -- Federal regulators said Thursday an experimental kidney cancer drug from GlaxoSmithKline may cause liver problems, potentially outweighing its ability to slow the disease.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments : 0